Actelion Pathways®

Actelion Pathways is available to all patients that have been prescribed VENTAVIS® (iloprost) Inhalation Solution. Through Actelion Pathways patients have access to Case Managers and Specialty Pharmacy nurses who can help the patient navigate the reimbursement and prescription process and provide the patient with training on the I-neb® Adaptive Aerosol Delivery (AAD®) System.

Actelion Pathways serves as the main point of contact for Actelion services and support programs. This program helps your patients by providing information and assistance with:

  • Prescription Assistance to help make sure your patients get their medicine in a timely manner
  • Insurance information and information on financial assistance programs - to help patients navigate the insurance process and to provide information on financial programs based on their eligibility
    • Support programs may be available to eligible patients taking VENTAVIS. The level of assistance may vary. Patients ineligible for financial support include, but are not limited to, those enrolled in Medicare, Medicaid, VA/DOD (Tricare), the Indian Health Services, or any other federally or state-funded healthcare program, or where prohibited by law.
 

Actelion Patient Services provides education and support from trained nurse counselors and respiratory therapists. Call 1-855-426-9277.

Getting your patients started on therapy

Actelion Pathways offers patients on VENTAVIS a clear path to getting on therapy. Patients receive support—from assistance with filling their prescriptions to ongoing education. Here's how it all comes together:

1. After a patient is prescribed VENTAVIS (iloprost): The process starts when Actelion Pathways receives the patient's prescription.

2. Support: Actelion Pathways provides support and services to help patients get started on treatment.

An Actelion Pathways Case Manager:
  • Helps patients with prescription assistance and can help them navigate the insurance process
A Patient Services Nurse Educator:
  • Helps answer questions your patient may have about starting VENTAVIS
  • Helps answer your patient's questions about the I-neb Adaptive Aerosol Delivery (AAD) System

3. The specialty pharmacy takes action:

  • Obtains insurance approval and determines your patient's benefit status for VENTAVIS and the I-neb AAD System
  • Notifies patients of their out-of-pocket expenses
  • Provides information on financial assistance programs, based on eligibility
    • Patients ineligible for financial support include, but are not limited to, those enrolled in Medicare, Medicaid, VA/DOD (Tricare), the Indian Health Service or any other federally or state-funded healthcare program, or where prohibited by law
  • Sends the VENTAVIS prescription and the I-neb AAD System directly to your patient
  • Sets up a training session between your patient and a VENTAVIS-trained nurse

If at any time your patients have a problem with their I-neb AAD System (for example, their I-neb AAD System is not working), they can call their specialty pharmacy, which is available 24 hours a day:

Accredo Specialty Pharmacy—1-866-344-4874

CVS/specialty—1-877-242-2738

4. The specialty pharmacy nurse meets with your patient: The VENTAVIS-trained specialty pharmacy nurse helps your patient understand how to take VENTAVIS with the I-neb AAD System. This training session can take place at their home or in your office.

5. Your patients receive ongoing support: Remember, Actelion is dedicated to helping your patients with their treatment. A support team is waiting to help them with answers to their questions about getting started on VENTAVIS and the I-neb AAD System.

INDICATION

VENTAVIS® (iloprost) Inhalation Solution is indicated for the treatment of pulmonary arterial hypertension (PAH) (WHO Group 1) to improve a composite endpoint consisting of exercise tolerance, symptoms (NYHA Class), and lack of deterioration. Studies establishing effectiveness included predominantly patients with NYHA Functional Class III-IV symptoms and etiologies of idiopathic or heritable PAH (65%) or PAH associated with connective tissue disease (23%).

IMPORTANT SAFETY INFORMATION

WARNINGS AND PRECAUTIONS

Risk of Syncope

  • Vital signs should be monitored while initiating VENTAVIS. Hypotension leading to syncope has been observed; VENTAVIS should therefore not be initiated in patients with systolic blood pressure less than 85 mmHg.

Pulmonary Venous Hypertension

  • Stop VENTAVIS immediately if signs of pulmonary edema occur; this may be a sign of pulmonary venous hypertension.

Bronchospasm

  • VENTAVIS inhalation may cause bronchospasm and patients with a history of hyperreactive airway disease may be more sensitive.

ADVERSE REACTIONS

Serious Adverse Events

  • Serious adverse events reported include congestive heart failure, chest pain, supraventricular tachycardia, dyspnea, peripheral edema, and kidney failure.

Adverse Events

  • Adverse events reported in a Phase 3 clinical trial occurring with a ≥3% difference between VENTAVIS patients and placebo patients were vasodilation (flushing) (27% vs 9%), increased cough (39% vs 26%), headache (30% vs 20%), trismus (12% vs 3%), insomnia (8% vs 2%), nausea (13% vs 8%), hypotension (11% vs 6%), vomiting (7% vs 2%), alkaline phosphatase increased (6% vs 1%), flu syndrome (14% vs 10%), back pain (7% vs 3%), tongue pain (4% vs 0%), palpitations (7% vs 4%), syncope (8% vs 5%), GGT increased (6% vs 3%), muscle cramps (6% vs 3%), hemoptysis (5% vs 2%), and pneumonia (4% vs 1%).

DRUG INTERACTIONS

Antihypertensives and Vasodilators

  • VENTAVIS has the potential to increase the hypotensive effect of vasodilators and antihypertensive agents.

Anticoagulants and Platelet Inhibitors

  • VENTAVIS also has the potential to increase risk of bleeding, particularly in patients maintained on anticoagulants or platelet inhibitors.

Please see full Prescribing Information.

INDICATION

VENTAVIS® (iloprost) Inhalation Solution is indicated for the treatment of pulmonary arterial hypertension (PAH) (WHO Group 1) to improve a composite endpoint consisting of exercise tolerance, symptoms (NYHA Class), and lack of deterioration. Studies establishing effectiveness included predominantly patients with NYHA Functional Class III-IV symptoms and etiologies of idiopathic or heritable PAH (65%) or PAH associated with connective tissue disease (23%).

IMPORTANT SAFETY INFORMATION

WARNINGS AND PRECAUTIONS

Risk of Syncope

  • Vital signs should be monitored while initiating VENTAVIS. Hypotension leading to syncope has been observed; VENTAVIS should therefore not be initiated in patients with systolic blood pressure less than 85 mmHg.

Pulmonary Venous Hypertension

  • Stop VENTAVIS immediately if signs of pulmonary edema occur; this may be a sign of pulmonary venous hypertension.

Bronchospasm

  • VENTAVIS inhalation may cause bronchospasm and patients with a history of hyperreactive airway disease may be more sensitive.

ADVERSE REACTIONS

Serious Adverse Events

  • Serious adverse events reported include congestive heart failure, chest pain, supraventricular tachycardia, dyspnea, peripheral edema, and kidney failure.

Adverse Events

  • Adverse events reported in a Phase 3 clinical trial occurring with a ≥3% difference between VENTAVIS patients and placebo patients were vasodilation (flushing) (27% vs 9%), increased cough (39% vs 26%), headache (30% vs 20%), trismus (12% vs 3%), insomnia (8% vs 2%), nausea (13% vs 8%), hypotension (11% vs 6%), vomiting (7% vs 2%), alkaline phosphatase increased (6% vs 1%), flu syndrome (14% vs 10%), back pain (7% vs 3%), tongue pain (4% vs 0%), palpitations (7% vs 4%), syncope (8% vs 5%), GGT increased (6% vs 3%), muscle cramps (6% vs 3%), hemoptysis (5% vs 2%), and pneumonia (4% vs 1%).

DRUG INTERACTIONS

Antihypertensives and Vasodilators

  • VENTAVIS has the potential to increase the hypotensive effect of vasodilators and antihypertensive agents.

Anticoagulants and Platelet Inhibitors

  • VENTAVIS also has the potential to increase risk of bleeding, particularly in patients maintained on anticoagulants or platelet inhibitors.

Please see full Prescribing Information.